Featured News

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

Showcasing the “brightest ideas and breakthroughs in digestive disease,” DDW 2020 includes recent studies and innovations in celiac disease and gluten-related disorders, some of which we have curated and summarized for you.

A recent review found that overall, the incidence of celiac disease has been rising since the second half of the 20th century into the 21st century in nearly every country where data on the disease are available.

More and more evidence is showing what many have long suspected: maintaining a truly gluten-free diet may not be possible.

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

There is currently no easy way to diagnose celiac disease in patients already following a gluten-free diet. In order for celiac disease blood tests to be accurate, patients on a gluten-free diet must undergo a “gluten challenge,” a temporary re-introduction of gluten into the diet, by consuming two slices of wheat-based bread daily for 6-8…

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…

Researchers are collecting blood samples to help develop new diagnostics that may not require gluten ingestion or a biopsy to confirm the diagnosis. 

ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.

On August 13th, 2019, Innovate Biopharmaceuticals, Inc. (Innovate) announced the first patient has been dosed in its Phase 3 clinical trial for patients with celiac disease. The CeD LA 3001 trial is testing larazotide acetate—also known as INN-202—as an adjunct treatment for patients with celiac disease still experiencing symptoms on a gluten-free diet. Larazotide acetate…